fashion -WSS

fashion

author：explore 2025-09-30 01:02:03 - browse：9531

Mel Evans/AP

Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs for $680 million. Merck will pay $23 per share, just over twice Harpoon’s market price entering the week.

The bolt-on deal comes as Merck’s top brass searches for ways to bolster the company’s revenue after it loses exclusivity on Keytruda, long the world’s most lucrative cancer drug. That could come as soon as 2028.

Keytruda, a PD-(L)1 inhibitor, works by turning off a “brake” on T cells, allowing roving immune cells to attack tumors. Harpoon’s pipeline belongs to a new class of cancer drugs designed to grab onto the T cells and tumor cells and bring them together.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Death of patient in Alzheimer’s trial raises question of possible risks

WSS

UnitedHealth quietly bought dozens of outpatient centers

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Precocious puberty in girls comes with mental health risks

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Weight bias in eating disorder treatment complicated by new weight loss drugs

Amylyx ALS drug fails large clinical trial

entertainment

fashion

Wikipedia

Trump demands the U.S. pay no more for drugs than other countries … again

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Cancer drug shortages should be causing more outrage

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Paxlovid study fails to answer questions over benefit for broader groups

Hollywood unions extend contract negotiations for actors

With FDA staff opposed to Sarepta therapy, top official intervened

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Death of patient in Alzheimer’s trial raises question of possible risks

explore

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Sen. Paul opposes bill to ban Chinese biotechs

Amylyx ALS drug failure raises questions and concerns

Why drug prescriptions should include diagnoses

STAT's guide to the next generation of CAR

First medicine developed to treat MASH expected to be approved soon

hotspot

hotspot

focus

focus